Application of salvia officinalis total phenolic acid extract in preparation of medicine with neurological function recovery effect after acute spinal cord injury

Through the total phenolic acid extract of Gancy sage, containing the best proportion of rosemary acid and sanphenolic acid B, it is used for the treatment of acute spinal cord injury, the problem of lack of effective drugs in the prior art is solved and the nerves are realized Functional recovery and inflammation suppression showed superior efficacy than single components.

CN119055699APending Publication Date: 2024-12-03CHINESE PEOPLES LIBERATION ARMY UNIT 32235
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411199055.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2024-06-18
Filing Date
2024-08-29
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

There is a lack of effective drugs in the prior art for early treatment of acute spinal cord injury, especially inability to fundamentally improve the prognosis of neurological function, and there are serious clinical complications.

Method used

The total phenolic acid extract of Gancy sage containing rosemary acid and sanphenolic acid B was prepared by macroporous adsorption resin column chromatography fixation process, and the optimal content range was determined to be 30% to 40% of rosemary acid. , sanphenolic acid B2% ~ 8%, is used to prepare drugs that have the effect of restoring nerve function after acute spinal cord injury.

Benefits of technology

It significantly improves and repairs motor function after acute spinal cord injury, inhibits the inflammatory response of spinal cord tissue, and promotes the recovery of neurological function. Its efficacy is better than single rosemary acid or sanphenolic acid B.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119055699A_ABST
    Figure CN119055699A_ABST
Patent Text Reader

Abstract

The invention discloses an application of a total phenolic acid extract of salvia officinalis in preparation of a medicine with a neurological function recovery effect after acute spinal cord injury, and relates to the technical field of medicines. The salvia officinalis total phenolic acid extract contains rosmarinic acid and salvianolic acid B (the mass ratio of the rosmarinic acid to the salvianolic acid B is 8: 1), can remarkably increase the BBB score and the inclined plate experiment angle of a rat with acute spinal cord injury, improves neuron injury in spinal cord tissues, reduces bleeding, reduces the content of serum inflammatory factors IL-1beta, IL-6, IL-18 and TNF-alpha, inhibits inflammatory response of the spinal cord tissues, and has a good application prospect. The improvement and repair of the motor function after acute spinal cord injury are promoted, and the curative effect is superior to that of the rosmarinic acid or salvianolic acid B which is independently used in the same dosage. The new medical application of the salvia officinalis total phenolic acid extract is found, and reference can be provided for research and development of acute spinal cord injury treatment drugs.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of medical technology, and particularly relates to application of a total phenolic acid extract of Salvia glabra in preparing a medicine having a neurological function recovery effect after acute spinal cord injury. Background Art

[0002] Acute spinal cord injury refers to acute loss of spinal cord function due to trauma, infection, inflammation or some autoimmune-related factors. Acute spinal cord injury is a catastrophic disabling and fatal disease that often causes multiple complications, seriously affecting the patient's physical and mental health and quality of life, and even endangering his life. The loss of motor function and the degree of recovery after spinal cord injury are not only related to the primary injury caused by mechanical external force to the spinal cord tissue, but also to the secondary injury caused by a series of pathological changes such as spinal cord hemorrhage, ischemia, hypoxia, etc. that occur after the injury. Secondary spinal cord injury begins within a few seconds after spinal cord injury and can last for several weeks. It mainly involves the immune system, nervous system and vascular system, including hemorrhage, ischemia, oxidative stress, inflammatory response, nerve cell death, demyelination and scar formation; it has the characteristics of progressive destruction, and the degree of tissue damage far exceeds the primary injury. Therefore, the clinical treatment of spinal cord injury should focus on reducing secondary damage to the spinal cord in order to reduce the mortality and disability rates and promote functional recovery; surgical decompression is the main treatment in the early stages, but there is currently a lack of specific drugs in the clinic for subsequent symptomatic treatment.

[0003] Methylprednisolone, also known as methylprednisolone, was once considered the first choice for the treatment of acute spinal cord injury because of its effects on inflammation inhibition and cell protection. However, in recent years, evidence-based medicine has found that there is more level I evidence that methylprednisolone shock therapy has serious clinical complications, and there is no decisive evidence to support that it can fundamentally improve the patient's neurological prognosis; guidelines formulated by organizations such as the American Association of Neurological Surgeons have adjusted the recommended level of hormone use from the original recommended use to not recommended use. Therefore, discovering and confirming drugs that can be used for early treatment of acute spinal cord injury to reduce secondary damage has become a focus and difficult issue in the field of clinical treatment research for acute spinal cord injury. Summary of the invention

[0004] Sage Salvia przewalskii ) belongs to the genus Salvia of the family Lamiaceae ( Salvia) plant, a perennial herb, with roots and rhizomes used as medicine, has a long history of medicinal use, and has the effects of regulating menstruation, promoting blood circulation, dispersing blood stasis, calming and relieving pain. It is mainly used to treat cardiovascular diseases and is widely used in folk applications. Its main root is thick and strong, with a high content of effective ingredients, rich resources and excellent quality. Its main chemical components are fat-soluble terpenoid compounds and water-soluble phenolic acid compounds, and it contains volatile oils and other ingredients.

[0005] The application team conducted a relatively systematic study on Salvia glabra and prepared a total phenolic acid extract of Salvia glabra containing mainly phenolic acid components such as rosmarinic acid and salvianolic acid B from the total ethanol extract of Salvia glabra using a macroporous adsorption resin column chromatography fixation process. Salvia przewalskii Total phenolic acid extract (SPE), since there is no relevant literature report on the recovery effect of total phenolic acid extract of S. glabra on the nerve function after acute spinal cord injury, the application team studied the application of total phenolic acid extract of S. glabra in the preparation of drugs with the effect of restoring nerve function after acute spinal cord injury, and after a large number of experiments, it was found that when the content of rosmarinic acid in the total phenolic acid extract of S. glabra is 30% to 40%, and the content of salvianolic acid B is 2% to 8%, it has a significant improvement and repair effect on the motor function after acute spinal cord injury, and the effect is significantly better than that of single rosmarinic acid or salvianolic acid B. The present invention has discovered a new medical use of total phenolic acid extract of S. glabra, and provides a solid and reliable theoretical basis and experimental reference for the application of total phenolic acid extract of S. glabra to treat acute spinal cord injury.

[0006] Specifically, in order to solve the technical problems existing in the above-mentioned background technology, the present invention provides the use of the total phenolic acid extract of Salvia glabra in the preparation of a drug having the effect of restoring neurological function after acute spinal cord injury.

[0007] As a further illustration of the present invention, the total phenolic acid extract of Salvia juncea contains rosmarinic acid and salvianolic acid B.

[0008] As a further illustration of the present invention, the rosmarinic acid content in the total phenolic acid extract of Salvia juncea is 30% to 40%, the salvianolic acid B content is 2% to 8%, and the mass ratio of the two is 6:1 to 9:1.

[0009] As a further illustration of the present invention, the rosmarinic acid content in the total phenolic acid extract of Salvia juncea is 34.32%, the salvianolic acid B content is 4.27%, and the mass ratio of the two is 8:1.

[0010] As a further illustration of the present invention, the total phenolic acid extract of Salvia lanceolata can promote the improvement and repair of motor function after acute spinal cord injury, improve neuronal damage in spinal cord tissue, inhibit the inflammatory response of spinal cord tissue, and promote the recovery of neurological function.

[0011] Compared with the prior art, the present invention has the following beneficial technical effects: the total phenolic acid extract of Salvia glabra provided by the present invention can promote the improvement and repair of motor function after acute spinal cord injury in rats, has a restorative effect on the neurological function after acute spinal cord injury in rats, and its therapeutic effect is better than that of using the same dose of rosmarinic acid or salvianolic acid B alone. BRIEF DESCRIPTION OF THE DRAWINGS

[0012] Figure 1 HPLC chromatogram of the main active ingredients in the total phenolic acid extract (SPE) of Salvia lanceolata (A. Rosemarinic acid and salvianolic acid B mixed reference substance, B. SPE; 1. Rosemarinic acid, 2. Salvianolic acid B) Figure 2 Standard curve for determination of the content of the main active components of the total phenolic acid extract (SPE) of Salvia officinalis (A. Rosmarinic acid, B. Salvianolic acid B) Figure 3 Comparison of body weight of rats in each group after treatment (A. 1 day of administration, B. 3 days of administration). x ̅±s , n=6) Figure 4 Comparison of organ coefficients of rats in each group after treatment (Aa. heart coefficient on the first day of administration, Ab. heart coefficient on the third day of administration, Ba. liver coefficient on the first day of administration, Bb. liver coefficient on the third day of administration, Ca. spleen coefficient on the first day of administration, Cb. spleen coefficient on the third day of administration, Da. kidney coefficient on the first day of administration, Db. kidney coefficient on the third day of administration. x ̅±s , n=6) Figure 5 Comparison of BBB scores and angles of the inclined board test in each group of rats after treatment (Aa. BBB score test on the first day of drug administration, Ab. BBB score test on the third day of drug administration, Ba. Inclined board test on the first day of drug administration, Bb. Inclined board test on the third day of drug administration. Note: Compared with group N, **** P <0.01; compared with group M, # P <0.05, ## P <0.01, ### P <0.001, #### P <0.0001; compared with the MP group, & P <0.05, && P <0.01; x ̅±s , n=6) Figure 6Comparison of serum inflammatory factors in rats of each group after treatment (Aa. IL-1β for 1 day, Ab. IL-1β for 3 days, Ba. IL-6 for 1 day, Bb. IL-6 for 3 days, Ca. IL-18 for 1 day, Cb. IL-18 for 3 days, Da. TNF-α for 1 day, Db. TNF-α for 3 days. Note: Compared with group N, ** P <0.01, *** P <0.001, **** P <0.0001; compared with group M, ## P <0.01, ### P <0.001, #### P <0.0001; compared with the MP group, & P <0.05, && P <0.01, &&& P <0.001. x ̅±s , n=6) Figure 7 Comparison of spinal cord histopathology of rats in each group (A. 1 day of administration, B. 3 days of administration. HE staining, 200×) Figure 8 Comparison of BBB scores and angles of the inclined board test in each group of rats after treatment (A. BBB score test on the 3rd day of drug administration, B. Inclined board test on the 3rd day of drug administration. Note: Compared with group N, **** P <0.0001; compared with group M, #### P <0.0001; compared with the SPE group, & P <0.05, &&& P <0.001. x ̅±s , n=6) DETAILED DESCRIPTION

[0013] The technical solutions in the embodiments of the present invention are described clearly and completely below. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0014] Example 1: Quality Control Experiment of Total Phenolic Acid Extract of Salvia officinalis 1 Materials and methods

[0015] 1.1 Instruments and reagents SQP Quintix 124-1CN electronic analytical balance (maximum load 120 g, graduation value 0.1 mg, Sartorius, Germany); Nexera-i LC-2040C 3D Plus high performance liquid chromatography system (including LC-40B XR binary pump, SIL-40C autosampler, CTO-40C column oven, SPD-40V diode array detector, Shimadzu, Japan).

[0016] Rosmarinic acid reference substance, purity ≥ 97%, batch number L2108770; salvianolic acid B reference substance, purity > 98%, batch number A2403260 (Shanghai Aladdin Biochemical Technology Co., Ltd.). Water was double distilled water. Other reagents were of analytical grade and were all products of Sinopharm Chemical Reagent Co., Ltd.

[0017] 1.2 Test drug: Salvia officinalis total phenolic acid extract (SPE), batch number 20220606, was prepared by our research group.

[0018] 1.3 Quality Control Methods The contents of the active ingredients rosmarinic acid and salvianolic acid B in SPE were determined by HPLC for quality control. 2 Results

[0019] 2.1 Chromatographic conditions The chromatographic column was Shimadzu C 18 Column (4.6 mm × 250 mm, 5 μm). The mobile phase was a mixed solution of acetonitrile (A) and 0.05% phosphoric acid aqueous solution (B), with gradient elution. The elution conditions were 0 min ~20 min, 12%A →20%A; 20 min ~60 min, 20%A →30%A; 60 min ~65 min, 30%A →12%A. The flow rate was 1.0 ml / min, the injection volume was 20 μl, the column temperature was 30°C, and the detection wavelength was 288 nm.

[0020] 2.2 Content determination results Under the above chromatographic conditions, the chromatographic peaks of rosmarinic acid and salvianolic acid B were completely separated, with retention times of 34.288 min and 42.351 min, respectively. The HPLC chromatograms are shown in Figure 1 Rosmarinic acid has good linear relationship in the concentration range of 37.5 μg / ml~750.0 μg / ml and salvianolic acid B has good linear relationship in the concentration range of 22.5 μg / ml~450.0 μg / ml. The standard curves of their content determination are shown in Figure 2The content of rosmarinic acid in SPE was determined to be 34.32%, and the content of salvianolic acid B was 4.27%, with a mass ratio of 8:1.

[0021] Since the contents of rosmarinic acid and salvianolic acid B in Sage officinalis extracts from different origins and batches are significantly different, the effects of different contents of rosmarinic acid and salvianolic acid B on the recovery of neurological function after acute spinal cord injury are also different. After a large number of experiments, the applicant team found that when the content of rosmarinic acid in the total phenolic acid extract of Sage officinalis is 30%~40%, and the mass of salvianolic acid B is 2%~8% (the mass ratio of the two is 6:1), the recovery of neurological function after acute spinal cord injury is not the same. ~9:1), more specifically, when the rosmarinic acid content in the total phenolic acid extract of Salvia officinalis is 34.32% and the salvianolic acid B content is 4.27% (the mass ratio of the two is 8:1), the effect on the recovery of neurological function after acute spinal cord injury is the best; therefore, the present invention selects the content with the best effect in the subsequent embodiments to carry out pharmacological animal experiments, and uses a single rosmarinic acid or a single salvianolic acid B to compare the effects of single rosmarinic acid or single salvianolic acid B on the recovery of neurological function after acute spinal cord injury. It is shown that the two active substances of rosmarinic acid and salvianolic acid B have a significant recovery effect on neurological function after acute spinal cord injury.

[0022] Example 2: Experimental study on the effect of total phenolic acid extract of Salvia officinalis on the recovery of neurological function after acute spinal cord injury 1 Materials and methods

[0023] 1.1 Instruments and reagents MP3002 electronic balance (maximum load 300 g, graduation value 10 mg, Shanghai Sunny Hengping Scientific Instrument Co., Ltd.); Donatello dehydrator (Diapath, Italy); JB-P5 embedding machine, JB-L5 freezing table (Wuhan Junjie Electronics Co., Ltd.); RM2016 pathology slicer (Shanghai Leica Instrument Co., Ltd.); G6012-1 adhesive slides (paraffin sections), G1101 universal tissue fixative (Wuhan Sevier Biotechnology Co., Ltd.); Eclipse C1 upright white light microscope (Nikon, Japan).

[0024] Rat serum interleukin-1β (IL-1β) enzyme-linked immunosorbent assay (ELISA) kit, batch number 20240202 (96T); rat serum IL-6 ELISA kit, batch number 20240207 (96T); rat serum IL-18 ELISA kit, batch number 20240206 (96T); rat serum tumor necrosis factor-α (TNF-α) ELISA kit, batch number 20240205 (96T) (Beijing Mairida Technology Co., Ltd.). Water was double distilled water. Other reagents were analytically pure and were all products of Sinopharm Chemical Reagent Co., Ltd.

[0025] 1.2 Test drugs Total phenolic acid extract of Salvia officinalis (SPE), batch number 20220606, was prepared by our research group. SPE was evenly suspended with 1% sodium carboxymethyl cellulose (CMC-Na) aqueous solution to prepare 5 mg / ml, 10 mg / ml, and 20 mg / ml SPE suspension solutions. Methylprednisolone sodium succinate (MP) for injection, specification 500 mg per vial (in terms of methylprednisolone), batch number EM8116, a product of Pfizer Manufacturing, Belgium. Before use, add injection water to dissolve to form a 25 mg / ml MP aqueous solution. The blank control solution was a 1% CMC-Na aqueous solution. The above solutions were all kept in the refrigerator and taken out in advance to be consistent with room temperature before administration.

[0026] 1.3 Experimental Animals SD rats, 72 in total, all male, weighing 200 g ~240 g, clean grade, purchased from Changzhou Cavens Laboratory Animal Co., Ltd., laboratory animal production license number SCXK (Su) 2021-0013, certificate number 202241779. They were fed with standard mouse food in the animal room, with free access to water and activities, room temperature of 20°C ~ 25°C, relative humidity of 20% ~ 35%, and continuous 12 h alternating light and dark fluorescent lighting. The experiment began after 7 days of adaptive feeding. This study was approved by the Ethics Committee of the 71st Army Group Hospital of the Army, Animal Welfare Ethics Approval Number LL-2022DW04. 1.4 Experimental methods

[0027] 1.41 Modeling method Rats were fasted for 12 h and randomly divided into 6 groups, namely sham operation group (group N), model control group (group M), positive drug methylprednisolone group (group MP), and SPE low, medium, and high dose groups (group SPE1, group SPE2, and group SPE3, respectively), with 12 rats in each group. The body weight was weighed using an electronic balance, and 1% sodium pentobarbital (dose 40 mg / kg) was injected intraperitoneally for anesthesia. After successful anesthesia, the rats were fixed in a prone position on a surgical fixation frame, the back was depilated and the skin was prepared, and the drape was laid after routine disinfection with iodine. A longitudinal incision was made on the posterior midline of the back to cut the subcutaneous fascia layer by layer to expose the paraspinal muscles, and a glass needle was used to bluntly dissect the muscles to expose the spinous process, lamina, and transverse process of the thoracic vertebra. Determine the position of the T10 thoracic vertebra, use bone scissors to make two transverse incisions between the spinous processes of T9 and T10, and between T10 and T11 and the corresponding lamina, and then make longitudinal incisions on both sides of the T10 thoracic vertebra at the connection between the transverse process and the lamina to form a rectangular incision boundary, then use bone rongeurs to bite the spinous process of the T10 thoracic vertebra and pull it up hard to "uncover" and remove the T10 lamina to form a square bone window, trim the edge of the bone window, and fully expose the spinal cord corresponding to T10.

[0028] The modified Allen's method was used to prepare the spinal cord injury model in rats of group M, MP and SPE. When hitting, the soft tissues on both sides of the spinal cord were pulled apart, fixed and stabilized. A round thin plastic gasket (3.5 mm in diameter) was disinfected on both sides with iodine and placed on the surface of the T10 spinal cord. A 10 g weight was dropped from a height of 2.5 cm to hit the T10 spinal cord. The weight was kept still and removed after 3 min, causing acute spinal cord injury (injury energy 60 g cm). After confirming the spinal cord injury, the incision was sutured layer by layer and the dressing was applied. The rats in group N underwent surgical laminectomy to fully expose the spinal cord corresponding to T10, but no hitting was performed. The incision was sutured layer by layer and the dressing was applied directly.

[0029] 1.42 Treatment Methods After dressing, rats in groups SPE1, SPE2, and SPE3 were gavaged with 5 mg / ml, 10 mg / ml, and 20 mg / ml SPE solutions at 10 ml / kg body weight, respectively; rats in groups N and M were gavaged with 1% CMC-Na aqueous solution at 10 ml / kg body weight, respectively; the drugs were administered once a day for 3 consecutive days. The MP group was intraperitoneally injected with 25 mg / ml MP aqueous solution. The administration time and dosage of rats were calculated according to the method for clinical treatment of patients with acute spinal cord injury in the instructions for injection of methylprednisolone sodium succinate (Pfizer Pharmaceuticals), that is, the first dose was 7.6 ml / kg body weight intraperitoneally, followed by 8.16 ml / kg body weight intraperitoneally at 0.75 h, 6.75 h, and 12.75 h, respectively, and 6.8 ml / kg body weight intraperitoneally at 18.8 h, and no more administration was given thereafter. 8×10 5U of penicillin sodium for 3 days to prevent infection. After the animals woke up, they were returned to the cages and kept alone, with free access to food and water. The bladders were squeezed to urinate 3 times a day until the rats could urinate autonomously. 1.5 Observation indicators

[0030] 1.51 Observation of physical signs and weight measurement of rats During the experiment, physical signs such as eating and drinking, urination, defecation, and mental state of rats in each group were observed and recorded daily, and the body weight of rats was weighed before feeding every day.

[0031] 1.52 Assessment of motor function On the 1st and 3rd day after modeling, 6 rats were selected from each group and weighed using an electronic balance. The BBB score and inclined board test were then performed. et al . Rho signaling pathway targeted to promote spinal cord repair. Journal of Neuroscience , 2002, 22(15): 6570-6577. Fournier AE, Takizawa BT, StrittmatterSM. Rho kinase inhibition enhances axonal regeneration in the injured CNS. Journal of Neuroscience , 2003, 23(4): 1416-1423.] BBB score. Rats were placed in a large activity area and their hind limb movements were observed by two blind people. The hind limb movement, trunk position and stability, gait, coordination, paw placement, toe clearance and tail position of the rats were jointly investigated. The average score of the left and right sides was taken as the final score. References [Zhang Guoping, Zhang Huanhu, Zhang Weidong. Effect of Panax notoginseng total saponins on the inclined board test score of rats with spinal cord injury. Chinese Modern Doctor, 2012, 50(1): 9-10.] Inclined board test was performed. Rats were placed on a homemade inclined board with the longitudinal axis of the rat body parallel to the longitudinal axis of the inclined board and the head raised toward the inclined board. The inclined board tilt angle slowly increased from 0°. The maximum angle of the rat staying on the inclined board for at least 5 s was recorded by two blind people. The test was repeated 3 times each time and the average value was recorded.

[0032] 1.53 Determination of serum inflammatory factor content After motor function assessment, the rats were anesthetized in the same way as in "1.41 Modeling Method", and the chest cavity was opened to fully expose the heart and aortic root. Blood was collected from the heart, and more than 5 ml of rat whole blood was collected and placed in a coagulant tube. The coagulant tube was immediately gently inverted 4 to 5 times to mix, and the sample was placed for 30 minutes to wait for full coagulation, and then centrifuged for 10 minutes at a centrifugal speed of 3500 to 4000 r / min. After the serum and blood clot were completely separated, the supernatant serum sample was taken and stored in a -80°C refrigerator. According to the steps in the kit instructions, the serum IL-1β, IL-6, IL-18 and TNF-α levels of rats in each group were determined.

[0033] 1.54 Tissue sampling After blood was drawn from the heart, the right atrium was cut open, and 200 ml of heparinized saline was perfused from the left ventricle using a syringe to flush the rat's organs. After the liver and sclera became pale, about 200 ml of 4% paraformaldehyde was used to perfuse the heart for 40 min. 1.5 cm of spinal cord tissue was cut from the spinal cord injury site and divided into 3 parts for pathological examination. The complete solid organs of the rat, heart, liver, spleen and kidney were taken, and the blood stains on the surface were rinsed with saline, and the surface water was absorbed. The weight of each organ of the rat was weighed using an electronic balance, and the data was recorded and the coefficient of each organ was calculated. The calculation method is: organ coefficient = rat organ weight / rat body weight.

[0034] 1.55 Pathological Observation Spinal cord tissue specimens were fixed with 4% paraformaldehyde for 24 h, routinely dehydrated, transparent, immersed in wax, embedded in paraffin, and sliced ​​into 5 μm sections. Pathological sections were prepared by hematoxylin and eosin (HE) staining and pathological observation was performed under a white light microscope.

[0035] 1.6 Statistical analysis SPSS 21.0 software was used for statistical analysis of experimental data, and the measurement data were expressed as mean ± standard deviation ( x ̅±s ). One-way analysis of variance was used to compare the differences in measurement data of rats in each group, and Tukey's method was used for pairwise comparison between groups. P The difference was statistically significant when the value was <0.05. 2 Results

[0036] 2.1 Effect of SPE on the physical signs of rats After the spinal cord was impacted, it was observed that the T10 spinal cord tissue was edematous and hemorrhaged in rats in all groups except the N group, and the dura mater was intact, purple-red, tense, and bulging; the rat tail swung spasmodically, the lower limbs fluttered like the body retracted, the tail was lifted high and then slowly fell down, showing slow paralysis, indicating that the spinal cord injury model was successfully established; while the rats in the N group did not have the above injury state. On the 1st and 3rd day of drug administration, there was no obvious change in the injury signs of rats in the M group, while the injury signs of rats in the MP group and SPE groups were improved, and the physical symptoms of rats in the MP group and the high-dose SPE group were more significantly improved.

[0037] Experiments have shown that SPE can improve the signs of injury in rats with spinal cord injury.

[0038] 2.2 Effects of SPE on the body weight and major organ coefficients of rats. There was no statistical difference in the body weight of rats in each group after 1-day and 3-day administration (all P < 0.05). P >0.05). The results are shown in Figure 3 There was no statistical difference in the heart coefficient, liver coefficient, spleen coefficient and kidney coefficient of rats in each group after 1 day and 3 days of drug administration (all P >0.05). The results are shown in Figure 4 .

[0039] Experiments have shown that SPE has no significant effect on the body weight of rats with spinal cord injury; it has no obvious toxicity to the heart, liver, spleen, and kidneys of rats with spinal cord injury, and has good organ safety for short-term use.

[0040] 2.3 Effect of SPE on BBB score and angle of inclined board test in rats. After 1 day and 3 days of drug administration, compared with group N, the BBB score and angle of inclined board test in group M, group MP and group SPE were significantly reduced (all P < 0.05). P <0.0001), showing obvious spinal cord injury. After 1 day of administration, the BBB scores of the MP group and the high-dose SPE group were significantly improved compared with the M group ( P <0.05, P <0.01); compared with the M group, the angles of the inclined plate test in the MP group and the SPE group were significantly increased (all P <0.0001). On the third day of administration, the BBB scores of the MP group and the SPE group were improved compared with those on the first day of administration. Compared with the M group, the BBB scores of the MP group and the medium- and high-dose SPE groups were significantly improved (P<0.01, P <0.05, P <0.001); compared with the M group, the angles of the inclined plate test in the MP group and the SPE group were significantly increased (respectively P <0.0001, P <0.01, P<0.001, P <0.0001). This indicates that after treatment with MP and medium- and high-dose SPE, the motor function of rats was significantly improved; the effect strength of SPE was positively correlated with the dose, and the degree of improvement in the BBB score of each SPE group and the angle of the inclined board test in the high-dose SPE group was equivalent to that of MP. Figure 5 .

[0041] Experiments have shown that SPE can significantly increase the BBB score and angle of the inclined board test in rats with acute spinal cord injury, and can promote the improvement and repair of motor function in rats after acute spinal cord injury.

[0042] 2.4 Effect of SPE on the levels of inflammatory factors in rat serum. After administration for 1 day and 3 days, the levels of IL-1β, IL-6, IL-18, and TNF-α in the serum of rats in group M were significantly increased compared with those in group N (all P<0.05). P <0.0001), that is, a strong inflammatory response occurred in the rats. After administration for 1 day, the IL-1β content in SPE of MP group and high-dose group was significantly reduced compared with that of M group (respectively P <0.0001, P <0.001); after 3 days of administration, the IL-1β levels in the MP and SPE groups were significantly lower than those in the M group ( P <0.0001, P <0.01, P <0.001, P <0.01). On the 1st and 3rd day of drug administration, the levels of IL-6, IL-18, and TNF-α in the MP and SPE groups were significantly lower than those in the M group (all P < 0.01). P <0.0001). It showed that after treatment with MP and SPE, serum IL-1β, IL-6, IL-18, and TNF-α were significantly inhibited; and the effect intensity of SPE was positively correlated with the dose, and the degree of inhibition of the above inflammatory factors in the high-dose SPE group was equivalent to that of MP. Figure 6 .

[0043] Experiments have shown that SPE can significantly inhibit the levels of serum IL-1β, IL-6, IL-18, and TNF-α in rats with acute spinal cord injury, improve the inflammatory environment in rats, and inhibit the inflammatory response of spinal cord tissue.

[0044] 2.5 Effect of SPE on pathological injury of rat spinal cord tissue After 1 day of administration, the morphological structure of neurons in the spinal cord tissue of rats in group N was normal, and no obvious inflammatory reaction was observed; there were multiple hemorrhages in the spinal cord tissue of group M, and a large number of red blood cell infiltrations were observed (red arrows); in the spinal cord tissue of group MP, a small number of neurons were shrunken (black arrows), the cells were stained darker, the nuclear cytoplasm boundary was unclear, the glial cells were slightly proliferated, and occasional perivascular congestion was observed (orange arrows); in the spinal cord tissue of group SPE1, a small number of capillary congestion and dilation were observed (orange arrows), and mild hemorrhage was observed in the central canal (red arrows); in the spinal cord of group SPE2, a few neurons were shrunken, the cells were stained darker, the nuclear cytoplasm boundary was unclear (black arrows), and no obvious proliferation of glial cells was observed; in the spinal cord of group SPE3, a few neurons were shrunken, the cells were stained darker, the nuclear cytoplasm boundary was unclear (black arrows), and no obvious proliferation of glial cells was observed. Results are shown in Figure 7 A.

[0045] After 3 days of administration, the nerve fibers in the spinal cord tissue of the rats in group N were intact and tight, and no obvious nerve cell damage and glial cell proliferation were observed; nerve cell shrinkage (black arrow), darker cell staining, and perivascular congestion (orange arrow) were observed in the spinal cord tissue of group M; a small amount of nerve cell shrinkage (black arrow) and darker cell staining were observed in the spinal cord tissue of group MP; a small amount of nerve cell shrinkage (black arrow) and darker cell staining were observed in the spinal cord tissue of group SPE1, and the cell staining was darker, the nuclear cytoplasm boundary was unclear, and perivascular congestion (orange arrow) was occasionally observed; in the spinal cord tissue of group SPE2, nerve cell shrinkage (black arrow) and darker cell staining were observed in the spinal cord tissue of group SPE3, nerve fibers were of different thicknesses, and there was no obvious abnormality. Results are shown in Figure 7 B.

[0046] Experiments have shown that SPE can improve neuronal damage in spinal cord tissue, reduce bleeding, and alleviate inflammatory response, and has a restorative effect on neurological function after acute spinal cord injury in rats.

[0047] Example 3: Comparative experiment on the effects of total phenolic acid extract of Salvia officinalis, rosmarinic acid and salvianolic acid B on the recovery of neurological function after acute spinal cord injury 1 Materials and methods

[0048] 1.1 Instruments and Reagents MP3002 electronic balance (maximum load 300 g, graduation value 10 mg, Shanghai Sunny Hengping Scientific Instrument Co., Ltd.). Water is double distilled water. Other reagents are analytically pure, all the same as in Example 2.

[0049] 1.2 Test drug: Total phenolic acid extract of Salvia officinalis (SPE), the specifications, batch number, origin and use method are the same as those in Example 2. Rosmarinic acid (RA) reference substance, specification 1 g, purity ≥ 97%, batch number R109805; salvianolic acid B (SA) reference substance, specification 100 mg, purity > 98%, batch number S579891 (Shanghai Aladdin Biochemical Technology Co., Ltd.). Before use, according to the average percentage content of RA and SA in SPE, the same dosage was calculated, RA was evenly suspended with 1% CMC-Na aqueous solution to prepare a 3.5 mg / ml RA suspension solution; SA was evenly suspended with 1% CMC-Na aqueous solution to prepare a 0.5 mg / ml SA suspension solution. The above solutions were all stored in a refrigerator and taken out in advance before administration to be consistent with room temperature.

[0050] 1.3 Experimental Animals 30 SD rats, all male, weighing 200 g to 240 g, clean grade, purchased from the same company, experimental animal production license number, and certificate number as in Example 2. The feeding conditions were the same as in Example 2. 1.4 Experimental methods

[0051] 1.41 Modeling Method Rats were fasted for 12 h and randomly divided into 5 groups, namely, sham operation group (N group), model control group (M group), SPE group, rosmarinic acid group (RA group), and salvianolic acid B (SA group), with 6 rats in each group. The modeling method and surgical procedure were the same as those in Example 2.

[0052] 1.42 Treatment Methods After dressing, rats in the SPE group were given 10 mg / ml SPE solution by gavage at 10 ml / kg body weight; rats in the RA group were given 3.5 mg / ml RA suspension solution by gavage at 10 ml / kg body weight; rats in the SA group were given 0.5 mg / ml SA suspension solution by gavage at 10 ml / kg body weight. Rats in the N and M groups were given 1% CMC-Na aqueous solution by gavage at 10 ml / kg body weight, once a day, for 3 consecutive days. Postoperative treatment, feeding, and disposal were the same as in Example 2. 1.5 Observation indicators

[0053] 1.51 Observation of physical signs of rats During the experiment, physical signs such as eating and drinking, urination, defecation, and mental state of rats in each group were observed and recorded daily, and the body weight of rats in each group was weighed before feeding every day.

[0054] 1.52 Motor Function Assessment Three days after modeling, BBB scoring and inclined board test were performed. The BBB scoring test and inclined board test methods were the same as those in Example 2.

[0055] 1.6 Statistical analysis SPSS 21.0 software was used for statistical analysis of experimental data, and the measurement data were expressed as mean ± standard deviation ( x ̅±s ). One-way analysis of variance was used to compare the differences in BBB scores and angles of the inclined board test among the rats in each group, and the Tukey method was used for pairwise comparisons between the groups. P The difference was statistically significant when the value was <0.05. 2 Results

[0056] 2.1 Effect of SPE on the physical signs of rats After the spinal cord was impacted, it was observed that the T10 spinal cord tissue was edematous and hemorrhaged in rats in all groups except the N group, and the dura mater was intact and purple-red, tense, and bulging; the rats' tails swung spasmodically, the lower limbs fluttered like retraction, the tails were lifted high and then slowly dropped, showing slow paralysis, indicating that the spinal cord injury model was successfully established; while the rats in the N group had no such injury symptoms. After 3 days of administration, the injury symptoms of the rats in the M group did not change significantly, while the injury symptoms of the rats in the SPE group, RA group, and SA group were all improved, and the improvement of the physical symptoms of the rats in the SPE group was better than that in the RA group and the SA group.

[0057] Experiments showed that SPE could improve the injury signs of rats with spinal cord injury, and the degree of improvement was better than that of the RA group and the SA group.

[0058] 2.2 Effect of SPE on BBB score and angle of inclined board test in rats After 3 days of administration, the BBB score and angle of inclined board test in rats in SPE, RA and SA groups were significantly reduced compared with those in N group ( P <0.0001), all showed obvious spinal cord injury. Compared with the M group, the BBB score of the SPE group was significantly improved ( P <0.0001), the angles of the inclined board test in the SPE group, RA group, and SA group were significantly improved ( P <0.0001). Compared with the SPE group, the BBB scores of the RA and SA groups were significantly lower ( P <0.05, P <0.001); compared with the SPE group, the angles of the inclined board test in the RA and SA groups were significantly reduced ( P <0.05, P <0.001). This shows that after SPE treatment, the motor function of rats was significantly improved; and SPE improved the BBB score and the angle of the inclined board test better than RA and SA. Figure 8 .

[0059] Experiments have shown that SPE can significantly increase the BBB score and angle of the inclined board test in rats with acute spinal cord injury, and can promote the improvement and repair of motor function in rats after acute spinal cord injury. Its therapeutic effect is better than that of using the same dose of RA or SA alone.

[0060] In summary, the total phenolic acid extract of Salvia glabra (rosmarinic acid content is 30%-40%, and salvianolic acid B content is 2%-8%) in the present invention can significantly increase the BBB score and the angle of the inclined board test in rats with acute spinal cord injury, improve neuronal damage in spinal cord tissue, reduce bleeding, alleviate inflammatory response, and reduce the levels of serum inflammatory factors IL-1β, IL-6, IL-18, and TNF-α, inhibit the inflammatory response of spinal cord tissue, and promote the recovery of neurological function.

[0061] The total phenolic acid extract of Salvia officinalis has good organ safety when used in the short term. It mainly promotes the improvement and repair of motor function after acute spinal cord injury in rats by improving the inflammatory environment in the rats' bodies and inhibiting the inflammatory response of spinal cord tissue. It has a restorative effect on the neurological function after acute spinal cord injury in rats. Its therapeutic effect is better than the same dose of rosmarinic acid or tannic acid B used alone.

[0062] It should be noted that, in this article, terms such as "comprises", "includes" or any other variations thereof are intended to cover non-exclusive inclusion, so that a process, method, article or apparatus that includes a series of elements includes not only those elements, but also other elements not explicitly listed, or also includes elements inherent to such process, method, article or apparatus.

[0063] Although embodiments of the present invention have been shown and described, it will be appreciated by those skilled in the art that various changes, modifications, substitutions and variations may be made to the embodiments without departing from the principles and spirit of the present invention, and that the scope of the present invention is defined by the appended claims and their equivalents.

Claims

1. Application of total phenolic acid extract of Salvia officinalis in the preparation of drugs with neurological function recovery effect after acute spinal cord injury.

2. The use of the total phenolic acid extract of Salvia officinalis as claimed in claim 1 in the preparation of a drug having an effect of restoring nerve function after acute spinal cord injury, characterized in that: The total phenolic acid extract of Salvia glabra contains rosmarinic acid and salvianolic acid B.

3. The use of the total phenolic acid extract of Salvia officinalis as claimed in claim 2 in the preparation of a drug having an effect of restoring nerve function after acute spinal cord injury, characterized in that: The rosmarinic acid content in the total phenolic acid extract of Salvia lanceolata is 30% to 40%, the salvianolic acid B content is 2% to 8%, and the mass ratio of the two is 6:1 to 9:

1.

4. The use of the total phenolic acid extract of Salvia officinalis as claimed in claim 3 in the preparation of a drug having an effect of restoring nerve function after acute spinal cord injury, characterized in that: The rosmarinic acid content in the total phenolic acid extract of Salvia glabra is 34.32%, and the salvianolic acid B content is 4.27%, and the mass ratio of the two is 8:

1.

5. The use of the total phenolic acid extract of Salvia lanceolata as claimed in claim 1 in the preparation of a drug having an effect of restoring nerve function after acute spinal cord injury, characterized in that: The total phenolic acid extract of Salvia lanceolata can promote the improvement and repair of motor function after acute spinal cord injury, improve neuronal damage in spinal cord tissue, inhibit the inflammatory response of spinal cord tissue, and promote the recovery of neurological function.